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A B S T R A C T
The cytokine interleukin-1 (IL-1) is a key contributor to neuroinflammation and brain injury, yet mechanisms by which IL-1 triggers neuronal injury remain
unknown. Here we induced conditional deletion of IL-1R1 in brain endothelial cells, neurons and blood cells to assess site-specific IL-1 actions in a model of cerebral
ischaemia in mice. Tamoxifen treatment of IL-1R1 floxed (fl/fl) mice crossed with mice expressing tamoxifen-inducible Cre-recombinase under the Slco1c1 promoter
resulted in brain endothelium-specific deletion of IL-1R1 and a significant decrease in infarct size (29%), blood-brain barrier (BBB) breakdown (53%) and neuro-
logical deficit (40%) compared to vehicle-treated or control (IL-1R1fl/fl) mice. Absence of brain endothelial IL-1 signalling improved cerebral blood flow, followed by
reduced neutrophil infiltration and vascular activation 24 h after brain injury. Conditional IL-1R1 deletion in neurons using tamoxifen inducible nestin-Cre mice
resulted in reduced neuronal injury (25%) and altered microglia-neuron interactions, without affecting cerebral perfusion or vascular activation. Deletion of IL-1R1
specifically in cholinergic neurons reduced infarct size, brain oedema and improved functional outcome. Ubiquitous deletion of IL-1R1 had no effect on brain injury,
suggesting beneficial compensatory mechanisms on other cells against the detrimental effects of IL-1 on endothelial cells and neurons. We also show that IL-1R1
signalling deletion in platelets or myeloid cells does not contribute to brain injury after experimental stroke. Thus, brain endothelial and neuronal (cholinergic) IL-
1R1 mediate detrimental actions of IL-1 in the brain in ischaemic stroke. Cell-specific targeting of IL-1R1 in the brain could therefore have therapeutic benefits in
stroke and other cerebrovascular diseases.
1. Background
Inflammation is a major contributor to stroke pathophysiology and
is therefore an attractive therapeutic target. A key mediator of in-
flammation is the pro-inflammatory cytokine interleukin-1 (IL-1)
(Dinarello et al., 2012). IL-1, expressed as two isoforms IL-1α and IL-1β,
is upregulated rapidly after experimental cerebral ischaemia and very
early expression is thought to occur in monocyte and macrophage
lineages, whilst slightly delayed expression occurs in astrocytes, neu-
rons, endothelial cells and invading immune cells (Ching et al., 2005;
Pinteaux et al., 2009; Denes et al., 2011). Preclinical studies using ex-
perimental animal models have demonstrated the importance of IL-1 in
stroke. Central or systemic administration of exogenous recombinant
IL-1β in rodents subjected to middle cerebral artery occlusion (MCAo)
exacerbates brain damage (Yamasaki et al., 1995; Stroemer and
Rothwell, 1998; McColl et al., 2007), whilst disruption of both IL-1α
and IL-1β in IL-1α/β knockout (KO) mice results in a 70% reduction in
infarct volume (Boutin et al., 2001). There is extensive experimental
evidence showing that blockade of IL-1 signalling using the IL-1 re-
ceptor antagonist (IL-1Ra) is protective in stroke and other forms of
brain injury, and early stage clinical trials of IL-1Ra in both ischaemic
and haemorrhagic stroke have to date shown potentially promising
results (Sobowale et al., 2016). However, the cellular mechanisms by
which IL-1 mediates brain injury following cerebral ischaemia remain
unknown.
IL-1 is known to exert its actions via binding and activation of its
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main functional IL-1 type 1 receptor (IL-1R1) (Sims et al., 1988). IL-1R1
is expressed on the cerebrovasculature (Konsman et al., 2004) and in
vitro studies also suggest that IL-1 acts in the brain through endothelial
cells (Thornton et al., 2010; Summers et al., 2013), whilst toxic actions
of IL-1 are mediated via cerebrovascular activation and transmigration
of neutrophils (Allen et al., 2012) in vitro. The knockdown of en-
dothelial IL-1R1 has been investigated in vivo (Li et al., 2011; Ching
et al., 2007) but has been focussed on ubiquitous knockdown rather
than inhibiting specific endothelial cell subsets, such as in the brain. IL-
1 acts both peripherally and centrally (Denes et al., 2013) but precise
brain specific actions have not yet been identified.
IL-1 also has diverse actions on neurons, including fast electro-
physiological firing (Diem et al., 2003; Desson and Ferguson, 2003),
potentiation of excitotoxicity and changes in neuronal gene expression
(Denes et al., 2011; Tsakiri et al., 2008). However, functional data
showing the effect of IL-1 on neurons and endothelial cells have been
obtained only from in vitro studies (Lazovic et al., 2005; Andre et al.,
2006), including our previous work showing IL-1 acts on neurons to
produce inflammatory mediators (Tsakiri et al., 2008), suggesting
neuronal signalling could contribute to detrimental neuroinflammatory
responses, though the contribution of cell specific IL-1 actions to brain
injury in vivo remains unknown.
The objective of this study was to determine the target cells of IL-1
action during ischaemic brain injury in mice. Tools to selectively and
conditionally delete IL-1R1 in different cell types in vivo have become
available recently (Abdulaal et al., 2016; Bruttger et al., 2015). Thus,
we investigated the contribution of endothelial cells and neurons to
ischaemic brain injury by deleting IL-1R1 from brain endothelial cell or
neurons (including cholinergic neuronal cells). We also assessed the
effects of IL-1R1 deficiency in platelets and myeloid cells, cell types that
are known to contribute to diverse forms of brain injury and that are
involved in systemic IL-1 actions (Thornton et al., 2010; Denes et al.,
2011; Iadecola and Anrather, 2011). We show that both brain en-
dothelial and neuronal IL-1R1 mediate the actions of IL-1 on brain in-
jury via functionally distinct mechanisms, some of which (i.e. effects on
cerebral perfusion) are apparent in the first hour after the ischaemic
insult. We also reveal that IL-1R1 on cholinergic neurons themselves
represent a potential therapeutic target against the detrimental effects
of IL-1 after acute brain injury.
2. Materials and methods
2.1. Experimental design
Animal procedures were carried out in accordance with the Animal
Scientific Procedures Act (1986) and the European Council Directive
2010/63/EU, and were approved by the Animal Welfare and Ethical
Review Body, University of Manchester, UK and the Animal Care and
Use Committee of the Institute of Experimental Medicine, Budapest,
Hungary. Experiments followed ARRIVE (Kilkenny et al., 2010) and
IMPROVE guidelines (Percie du Sert, 2017). A code was allocated to
each animal by a non-experimenter and was randomly assigned to
different treatment groups. During all surgical procedures and func-
tional tests the experimenter was blinded to treatment.
2.2. Animals
All mice were on a C57BL/6J background and only males were
used. Brain endothelial-specific IL-1R1 knockout (KO) mice were gen-
erated by crossing mice in which exon 5 of the Il1r1 gene is flanked with
loxP sites [IL-1R1 floxed (fl/fl)] (Abdulaal et al., 2016) with mice ex-
pressing Cre recombinase under the promoter of the thyroxine trans-
porter (Slco1c1) that is specifically expressed in brain endothelial cells
(Ridder et al., 2011) (thereafter named IL-1R1fl/fl Δ Slco1c1) (Fig. 1A).
Brain endothelial IL-1R1 deletion was achieved by injection of tamox-
ifen (2mg/100 µl in corn oil, Sigma-Aldrich) for five consecutive days
in 6–9week old male mice. Controls were IL-1R1fl/fl Δ Slco1c1 male mice
injected with vehicle (corn oil) as well as IL-1R1fl/fl mice treated with
tamoxifen. Mice allocated for the detection of IL-1R1 expression were
culled 0, 7 and 14 days after tamoxifen administration, whilst mice
allocated for experimental stroke underwent surgery at 21 days after
the start of tamoxifen or vehicle administration. Tamoxifen inducible
nestin-Cre mice were crossed with IL-1R1fl/fl mice to delete IL-1R1 in
neurons following two consecutive administrations of 2mg/100 μl ta-
moxifen (48 h apart) in 2–4week old male mice (thereafter named IL-
1R1fl/fl Δ Nestin). Ubiquitous IL-1R1 KO mice (named IL-1R1−/−) were
generated by crossing IL-1R1fl/fl mice with K14-Cre mice, as previously
reported (Couzin-Frankel, 2012). To delete IL-1R1 selectively from
cholinergic neurons, IL-1R1fl/fl mice were crossed with ChAT-cre mice
(IL-1R1fl/fl Δ ChAT). To selectively and constitutively delete IL-1R1 in
myeloid cells or platelets, IL-1R1fl/fl mice were crossed with LysM-Cre
mice (IL-1R1fl/fl Δ LysM) or PF4-Cre mice (IL-1R1fl/fl Δ PF4), respectively.
All animals were maintained at 21 ± 1 °C, 55 ± 10% humidity, in a
12 h light-dark cycle with free access to food and water.
In total, 10 IL-1R1fl/fl Δ Slco1c1 animals injected with vehicle, 11 IL-
1R1fl/fl Δ Slco1c1 animals injected with tamoxifen and 11 IL-1R1fl/fl an-
imals injected with tamoxifen, were used in this study to determine the
effect of brain endothelial cell IL-1R1 deletion; 10 IL-1R1fl/fl and 10
tamoxifen-treated IL-1R1fl/fl Δ Nestin were used to assess the effect of
neuronal IL-1R1 deletion; 13 IL-1R1fl/fl mice and 10 IL-1R1−/− mice
were used to determine the effect of ubiquitous IL-1R1 deletion; 9 IL-
1R1fl/fl Δ ChAT mice, 10 IL-1R1fl/fl mice, 14 IL-1R1fl/fl mice, 14 IL-1R1 fl/
fl Δ PF4 and 12 IL-1R1 fl/fl Δ LysM mice were used to assess the effect of IL-
1R1 deletion in cholinergic neurons, platelets or myeloid cells, re-
spectively. The pre-determined inclusion criteria for analysis were as
follows; decline in Doppler signal of at least 70%, no subarachnoid
haemorrhages and survival to 24 h. Subarachnoid haemorrhage was
identified post-mortem by the presence of excessive bleeding on the
external surface of the brain, typically close to the filament location.
Animals excluded from analysis due to early mortality included; two IL-
1R1fl/fl Δ Slco1c1 mice treated with vehicle and two with tamoxifen, four
IL-1R1fl/fl, one IL-1R1fl/fl Δ Nestin and two IL-1R1fl/fl Δ ChAT animal due to
surgical artefacts, whilst a single IL-1R1fl/fl Δ Slco1c1 vehicle-treated
animal was culled early for welfare. Exclusions for cerebral haemor-
rhages included; two IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle, three
with tamoxifen, one IL-1R1fl/fl animal treated with tamoxifen and one
IL-1R1fl/fl Δ Nestin animal. Four additional mice were excluded from
analysis pre hoc based on the criteria detailed above in that an in-
sufficient drop (> 70%) in cerebral blood flow was observed. In total
there were 23 mice excluded from the study, which is 14.6% of the total
used.
2.3. Focal cerebral ischaemia
Anaesthesia was induced by inhalation of 4% isoflurane (30%
oxygen and 70% nitrous oxide gas mix, AbbVie Ltd, UK or Linde Ltd,
Hungary) and was maintained at 1.75%. Body temperature was mon-
itored throughout surgery (via rectal probe) and maintained at
37 °C ± 0.5 °C using a heating blanket (Harvard Apparatus,
Edenbridge, Kent, UK). A laser Doppler blood flow monitor (Oxford
Optronix, Abingdon, UK) was used to monitor cerebral blood flow
(CBF). Focal cerebral ischaemia was induced by MCAo based on a
previously described protocol (Wong et al., 2014). Briefly, a hole was
made into the temporalis muscle (6 mm lateral and 2mm posterior from
bregma) to allow a 0.5 mm diameter flexible laser-Doppler probe to be
fixed onto the skull and secured in place by tissue adhesive (Vetbond,
UK). A midline incision was made on the ventral surface of the neck and
the right common carotid artery isolated and ligated. Topical anaes-
thetic (EMLA, 5% prilocaine and lidocaine, AstraZeneca, UK) was ap-
plied to skin incision sites prior to incision. The internal carotid artery
and the pterygopalatine artery were temporarily ligated. A 6-0 mono-
filament (Doccol, Sharon, MA, USA) was introduced into the internal
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carotid artery via an incision in the common carotid artery (en-
dothelial-specific IL-1R1 deletion study) or via the external carotid ar-
tery (ubiquitous, neuronal-specific-, myeloid cell-specific and platelet-
specific IL-1R1 deletion studies). The filament was advanced approxi-
mately 10mm distal to the carotid bifurcation, beyond the origin of the
middle cerebral artery. Relative CBF was monitored for the first
30–45min following MCAo, during which time relative CBF had to
reduce by at least 70% of pre-ischaemic values for inclusion. After
30min of occlusion (endothelial-specific IL-1R1 deletion study) or
45min of occlusion (ubiquitous, neuronal-specific-, myeloid cell-spe-
cific and platelet-specific IL-1R1 deletion studies) the filament was
withdrawn back into the common carotid artery to allow reperfusion to
take place. The wound was sutured and mice received a subcutaneous
bolus dose of saline for hydration (500 µl) and a general analgesic
(Buprenorphine, 0.05mg/kg injected subcutaneously, Vetergesic, UK).
Animals were kept at 26–28 °C until they recovered from anaesthesia
and surgery, before being transferred back to ventilated cages sus-
pended over a heating pad with free access to mashed food and water in
normal housing conditions.
2.4. Tissue processing
Animals were perfused transcardially with 0.9% saline followed by
4% paraformaldehyde (PFA) under either terminal 3% isoflurane (30%
oxygen and 70% nitrous oxide gas mix) or ketamine-xylazine anaes-
thesia. Brains were then removed and left to post-fix for 24 h either in
4% PFA or in 10% sucrose 4% PFA before being transferred either to
30% sucrose or to 10% sucrose-PBS. After 24 h in 10% or 30% sucrose,
brains were sectioned into 25–30 µm coronal sections using a sledge
microtome (Bright, Cambridgeshire, UK or Leica, Germany) for sub-
sequent Cresyl violet staining and immunohistochemistry.
2.5. Functional outcomes
Animals were assessed for neurological deficits 24 h after MCAo a
using a 5-point scoring system (Iadecola et al., 1997). The neurological
scores were as follows: 0, normal motor function; 1, flexion of torso and
contralateral forelimb when mouse was lifted by the tail; 2, circling to
the contralateral side when mouse is held by the tail on a flat surface,
but normal posture at rest; 3, leaning to the contralateral side at rest, 4,
no spontaneous motor activity. In IL-1R1fl/fl Δ ChAT mice functional
outcome has also been assessed by a composite neurological score
Fig. 1. Brain endothelial IL-1R1 deletion reduces infarct volume and BBB permeability and improves neurological function. IL-1R1fl/fl Δ Slco1c1 (Brain endothelial-
specific IL-1R1) mice were generated by crossing IL-1R1fl/fl mice (exon 5 of the Il1r1 gene flanked with loxP sites) with Slco1c1 CreERT2 mice (expressing Cre
recombinase under the promoter of the thyroxine transporter (A). IL-1R1 protein expression was reduced over time in blood vessels identified by CD31 im-
munostaining in IL-1R1fl/fl Δ Slco1c1 animals after tamoxifen treatment to total deletion by day 14 (B). IL-1R1 deletion in brain endothelial cells (IL-1R1fl/fl Δ Slco1c1
mice treated with tamoxifen) reduced infarct volume as assessed on cresyl violet stained brain sections (C), IgG leakage (D) and improved neurological function (E)
compared to control group (IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle). IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle; n= 10, IL-1R1fl/fl Δ Slco1c1 mice treated with
tamoxifen; n= 11, IL-1R1fl/fl treated with tamoxifen; n= 11. *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. All parametric data are expressed as
means ± SEM, medians are shown in the case of neurological scores. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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optimized for mice to obtain a more comprehensive readout (Orsini
et al., 2012; Clark et al., 1997). Composite scores range from 0 (healthy
mice) to 56 (worst performance) by adding up scores from 13 categories
as follows: hair (0–2), ears (0–2), eyes (0–4), posture (0–4), sponta-
neous activity (0–4), and epileptic behavior (0–12), and focal deficits:
body symmetry (0–4), gait (0–4), climbing on a surface held at 45°
(0–4), circling behavior (0–4), front limb symmetry (0–4), compulsory
circling (0–4), and whisker response to a light touch (0–4). Results are
expressed as composite neurological score.
2.6. Laser speckle contrast imaging (LSCI)
At the end of the MCAo surgery, mice were transferred to the ste-
reotaxic frame and LSCI measurements performed 30min after re-
perfusion under isoflurane anaesthesia, using a PeriCam PSI High
Resolution system (Perimed AB, Järfälla-Stockholm, Sweden). To assess
CBF changes in different groups of mice in a uniform manner, tamox-
ifen-treated IL-1R1fl/fl Δ Slco1c1 mice and IL-1R1fl/fl Δ Nestin mice together
with tamoxifen-treated control IL-1R1fl/fl mice were subjected to MCAo
for 45min (left side occluded). LSCI measurements were performed
30min after reperfusion. The skin on the top of the skull was opened
and imaging performed through the intact skull bone to visualize cor-
tical perfusion changes (Winship, 2014) for 10min at 16 frames/sec in
20 µm/pixel resolution, using a 10×10mm field of view. To evaluate
recovery of blood flow in the penumbra after stroke, perfusion changes
were assessed in three adjacent regions of interest (ROI) in the primary
MCA area (Fig. 5A). LSCI is particularly sensitive to assess perfusion
changes in the microcirculation. The area of cortical sinusoids have
been excluded from ROIs and only measurements without motion ar-
tefacts have been analysed to minimize bias (Eriksson et al., 2014;
Dunn, 2012). Area under the curve (AUC) values over the 10min
imaging period for each ROI were determined and data expressed as
percentage values of the corresponding contralateral ROI.
2.7. Histology and immunohistochemistry
Lesion volumes were measured using Cresyl violet staining, as
previously described (McColl et al., 2007). For each brain, infarcts were
measured on defined coronal sections (using image J), spaced ap-
proximately 360 µm apart. Each defined coronal section, with its brain
co-ordinates and lesion was integrated to estimate total lesion volume
for each brain and corrected for oedema.
Blood-brain-barrier (BBB) permeability was assessed by peroxidase-
based immunohistochemistry for circulating IgG infiltration in the
brain. Endogenous peroxidase activity (0.3% H202 in dH2O for 10min)
and non-specific staining [5% normal horse serum, 0.3% triton in
phosphate buffered saline (PBS) for 10min] were blocked, and sections
incubated in biotinylated anti-mouse IgG antibody (1:500, #BA-2000,
Vector Laboratories, UK) for 2 h. Sections were then washed and in-
cubated with avidin–biotin–peroxidase complex (1:500, Vectastain
Elite ABC HRP Kit, #PK-6100, Vector Laboratories, UK), and detected
by colorimetry using a diaminobenzidine (DAB) solution (0.05% DAB,
0.005% H2O2 in dH2O). Sections were left to dry, before being mounted
using DPX mounting medium (Fisher Scientific, UK), cover slipped and
imaged using an Olympus BX51 upright microscope with Coolsnap ES
camera (Photometrics, UK) for image capture. The total IgG volume for
the brain was determined by measuring IgG on individual sections and
integrating them to determine total IgG volume, as described earlier for
lesion volume.
2.8. Immunofluorescence
Brain sections were incubated with blocking buffer consisting of 5%
normal donkey serum (Jackson laboratories, Bar Harbor, ME, USA), 1%
bovine serum albumin (BSA), 0.1% Triton X-100, 0.05% Tween 20
(Sigma-Aldrich), 0.2M Glycine (Fisher Scientific) in PBS for 1 h.
Blocking buffer was then removed and sections were incubated with
primary antibody, diluted in primary antibody buffer (1% BSA, 0.3%
Triton X-100 in PBS), with Lectin (1:100, Lycopersicon esculentum,
#L0651, Sigma-Aldrich) at 4 °C overnight. Primary antibodies used in
this study included; goat anti-IL-1R1 (1:100, #AF771, R & D Systems,
UK), sheep anti-VWF (1:100, Abcam, UK), rabbit anti-Iba1 (1:1000,
#019–19741, Wako, USA), goat ant-intracellular adhesion molecule 1
(ICAM-1, 1:200, #AF796, R&D Systems, UK), goat anti-vascular cell
adhesion protein 1 (VCAM-1, 1:100, R&D Systems, UK), SJC4
(1:10,000, kindly gifted by Professor Daniel Anthony, University of
Oxford, UK), rat anti-CD45 (1:250, #MCA1388, AbD Serotec, UK),
goat-anti MPO (1:250, #AF3667, Novus Biologicals, UK), mouse anti-
neurofilament-H (1:500, #SMI-32P, Covance, USA), rabbit anti-P2RY12
(1:500, #55043AS AnaSpec, Belgium), mouse anti-Cre recombinase
(1:500, #MAB3120, Millipore, Germany) and chicken-anti PGP9.5
(1:500, #ab72910, Abcam, UK), rabbit anti- Annexin V (1:250,
#NB100-1930, Novus Biologicals, UK) and mouse-anti NeuN (1:500,
#MAB377, Millipore, Germany). Sections were washed in 0.1% Tween
in PBS, and incubated with secondary antibodies diluted in 0.05%
tween in PBS. Secondary antibodies consisted of Alexa-Fluor 488 (1:500
rabbit, goat, ThermoFisher, UK), Alexa-Fluor 594 (1:500, sheep, goat,
ThermoFisher, UK) and Alexa-Fluor 350 (1:100, streptavidin,
ThermoFisher, UK), donkey anti-rabbit A488 (1:500, # A21206,
Invitrogen, USA), streptavidin DyL405 (1:500, #016-470-084, Jackson
ImmunoResearch, USA), donkey anti-goat A488 (1:500, #A11055,
Invitrogen, USA), donkey anti-rat A594 (1:500, #A21209, Invitrogen,
USA) and donkey anti-rabbit A647 (1:500, #711-605-152, Jackson
ImmunoResearch, USA). After a 2 h incubation, secondary antibodies
were removed, and sections were washed with 0.1% Tween in PBS,
mounted on glass slides and left to dry in the dark, before being cover
slipped with mounting medium (ProLong Gold without DAPI,
ThermoFisher, UK).
2.9. Image analysis
Analyses for immunohistochemistry were conducted on coronal
sections taken at the same co-ordinates (approximately +1mm ante-
rior to bregma), and both ipsilateral and contralateral hemispheres (to
the side of the brain lesion) regions were measured in each animal.
Neutrophils were counted in the middle of the striatum and in the
cerebral cortex. Analysis of vascular markers (ICAM-1, VCAM-1) and
Iba1 immunostaining was conducted in the penumbra region of the
cortex and in the striatum. The activation states of Iba1-positive mi-
croglia were scored based on the morphology, as described previously
(40), or numbers of activated microglia counted based on the levels of
Iba1 and CD45 expression and morphology. Briefly, scoring was as
follows: 0, Resting/Ramified; 1, De-ramifying/Re-ramifying; 2,
Activated/Amoeboid; 3, Clustered & activated. Image analysis was
carried out blinded to the experimental group status on three randomly
selected ROI/brain region/slice on three coronal slices/animal.
2.10. Statistical analysis
Sample size for experimental stroke studies were determined by a
priori power calculation using G*Power 3.1.9.2 with mean differences
and standard deviations based on pilot studies and previous experi-
ments (power 80%, α 0.05). Data were assessed for normal distribution
using the Shapiro-Wilk W-test in order to determine parametric or non-
parametric analysis. Lesion volume and BBB breakdown were analysed
with one-way ANOVA followed by post-hoc Tukey multiple compar-
isons between treatments groups. Mann-Whitney test was used to
analyse differences between control and IL-1R1fl/fl Δ ChAT mice due to
the lack of normality of data sets. Neurological scoring was analysed
with non-parametric Mann-Whitney test (2 groups) or Kruskal-Wallis
test combined with Dunn’s multiple comparisons test.
Immunofluorescence data were analysed by two-way ANOVA, and post-
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hoc Tukey’s multiple comparisons between matched hemisphere and
treatment groups. Significant difference was considered for p < 0.05.
3. Results
3.1. Brain endothelial IL-1R1 deletion reduces infarct volume, BBB
permeability and improves neurological function
First, we investigated brain injury after targeted deletion of IL-1R1
from the cerebrovasculature. IL-1R1fl/fl Δ Slco1c1 animals (Fig. 1A) in-
jected with tamoxifen showed reduced IL-1R1 protein expression in
cerebral blood vessels at day 7 and IL-1R1 expression was completely
ablated on day 14 (Fig. 1B). Experimental animals in this study were
used at day 21 onwards.
Deletion of IL-1R1 in brain endothelial cells (IL-1R1fl/fl Δ Slco1c1
mice) significantly reduced both ischaemic infarct (29% decrease,
Fig. 1C, 95% CI: 4.33 to 27.99, p= 0.0058; F (2, 29)= 6.67) and IgG
leakage (53% decrease, Fig. 1D, 95% CI: 15.27 to 46.47, p < 0.0001; F
(2, 27)= 17.82) compared to vehicle-treated IL-1R1fl/fl Δ Slco1c1 ani-
mals, whilst IL-1R1fl/fl animals treated with tamoxifen had infarcts and
BBB injury based on IgG leakage comparable to vehicle-treated IL-
1R1fl/fl Δ Slco1c1 mice (Fig. 1C and D). IL-1R1 deletion in brain en-
dothelial cells resulted in reduced neurological deficits (40% decrease,
Fig. 1E, p < 0.0065) compared to vehicle-treated IL-1R1fl/fl Δ Slco1c1
mice, with experimental groups correlating similarly to infarct volume
and BBB disruption.
3.2. Brain endothelial IL-1R1 deletion reduces cerebrovascular activation
and neutrophil migration
As reported previously (Wang et al., 1994), MCAo increased cere-
bral vascular expression of ICAM-1 (Fig. 2A and B) and VCAM-1
(Fig. 2C and D) in the ipsilateral hemisphere, compared to the con-
tralateral hemisphere [F (1, 25)= 113.8, p≤ 0.001; F (1, 25)= 98.82,
p≤ 0.001, respectively]. However, brain endothelial IL-1R1 deletion
reduced cerebrovascular activation in IL-1R1fl/fl Δ Slco1c1 mice by 50%
(95% CI: 1.86 to 12.95, p=0.007) for ICAM-1 (Fig. 2B) and 55% (95%
CI: 1.81–33.08, p=0.027) for VCAM-1 (Fig. 2D) compared to vehicle-
treated animals [F (2, 25)= 8.919, p=0.0012; F (2, 25)= 7.043,
p=0.0038, respectively]. Cerebral activation of VWF was reduced by
56% though this was not significant (95% CI: −4.71 to 33.42,
p=0.1668; F (2, 25)= 2.412, p=11.02). Tamoxifen-treated IL-1R1fl/
fl mice had equivalent levels of ICAM-1 (Fig. 2B) and VCAM-1 (Fig. 2D)
to vehicle-treated IL-1R1fl/fl Δ Slco1c1 mice.
We have demonstrated previously that IL-1 actions on brain en-
dothelial cells in vitro contribute to neutrophil infiltration and sub-
sequent neurotoxicity (Allen et al., 2012). Since our data demonstrate
that brain endothelial IL-1R1 contributes to brain damage and BBB
dysfunction, we next investigated the possible mechanisms underlying
brain endothelial IL-1R1 deletion-induced ischaemic damage, by as-
sessing stroke induced neutrophil infiltration after IL-1R1 deletion.
After MCAo, neutrophils migrate to the area of infarct, in sig-
nificantly increased numbers compared to the undamaged contralateral
side (Fig. 3A). IL-1R1fl/fl Δ Slco1c1 mice treated with tamoxifen, showed
almost a complete loss (94% reduction, p= 0.0114) of neutrophil mi-
gration compared to vehicle treatment (95% CI: 17.95 to 154.4,
p= 0.0114; F (2, 25)= 6.093), whilst IL-1R1fl/fl animals treated with
tamoxifen had similar neutrophil numbers compared to vehicle-treated
IL-1R1fl/fl Δ Slco1c1 animals (Fig. 3B). Although IL-1R1 deletion on the
brain endothelium dramatically reduced neutrophil migration induced
by cerebral ischaemia, there was no effect on microglial activation, and
the number of microglia were unchanged (data not shown) compared to
vehicle-treated IL-1R1fl/fl Δ Slco1c1 or IL-1R1fl/fl control animals after
MCAo (Fig. 3C and D).
3.3. Neuronal IL-1R1 deletion reduces infarct volume and leads to altered
microglia-neuron interactions in the penumbra
To genetically delete IL-1R1 effectively from most neurons we used
the nestin promoter-driven Cre recombinase expression that is ex-
pressed in neurons and a subset of glial precursors. Using our tamoxifen
induction protocol we found that Cre expression was mainly confined to
neurons in IL-1R1fl/fl Δ Nestin mice 48 h after tamoxifen administration
(Fig. 4A). Experimental stroke in IL-1R1fl/fl Δ Nestin mice resulted in
significantly smaller (25% reduction, p=0.0379) brain injury (Fig. 4B)
compared to IL-1R1fl/fl mice that received identical tamoxifen treat-
ment. In spite of this marked reduction in infarct volume, only a non-
significant trend of reduced brain oedema was observed (Fig. 4C),
whereas BBB breakdown was not affected in these mice (data not
shown) and no difference was observed in neurological outcome
(Fig. 4D). To understand these findings, we assessed changes in vascular
activation and neutrophil recruitment in IL-1R1fl/fl Δ Nestin and IL-1R1fl/
fl mice 24 h after cerebral ischaemia, as above. In contrast to the effect
of brain endothelial IL-1R1 deletion, no changes in ICAM-1-positive
blood vessels or the total number of CD45-positive leukocytes or neu-
trophils were found in the brain (Fig. 4E–G). The majority of CD45-
positive leukocytes were neutrophils containing myeloperoxidase
(Fig. 4E ii). The numbers of activated microglia were also not different
(Fig. 4H), suggesting that an absence of IL-1R1 signalling in the brain of
IL-1R1fl/fl Δ Nestin mice does not influence vascular and microglial in-
flammatory actions in response to ischaemic injury. Since our previous
research has revealed a key role for microglia in protecting injured
neurons by shaping neuronal network activity and excitotoxicity, we
assessed microglial process coverage of neurons as an indicator of al-
tered neuronal activity and microglia-neuron interactions (Szalay et al.,
2016). Microglial process coverage was significantly increased (by
22.29%, p= 0.0043) in the ischaemic penumbra of IL-1R1fl/fl Δ Nestin
mice (Fig. 4I), where microglia contacted both NeuN-positive neurons
and Annexin V-positive cells beyond the zone of viable neurons
(Fig. 4J). This suggested that neuronal IL-1R1 signalling may alter
neuronal activity and /or protective microglia neuron interactions.
3.4. Brain endothelial, but not neuronal IL-1R1 deletion improves early
perfusion deficits after cerebral ischaemia
To investigate whether site-specific IL-1 actions influenced brain
perfusion early enough to influence the evolution of the infarct, we
assessed cerebral perfusion changes 30min after the induction of re-
perfusion in three adjacent regions of interest (ROI; Fig. 5A). In the
absence of endothelial IL-1R1, a significantly smaller perfusion deficit
was observed in the ipsilateral hemisphere at the MCA area
[p=0.0017, F (1, 32)= 11.74], which was apparent at both MCA2
and MCA3 ROIs (95% CI: 0.4004 to 49.09, p= 0.0451; 95% CI: 0.4911
to 49.18, p= 0.0440, respectively) compared to control mice (Fig. 5B
and C). This phenomenon was less obvious in the lateral cortical areas
(core of primary MCA territory) and was more apparent in the midline
and rostral-caudal zones with more collateral supply (Fig. 5B, MCA2,
MCA3 ROIs on Fig. 5C). We also assessed cerebral perfusion changes in
IL-1R1fl/fl Δ Nestin mice. In contrast to our findings after endothelial IL-
1R1 deletion, no differences were observed between IL and 1R1fl/fl Δ
Nestin and IL-1R1fl/flmice (Fig. 5D and E), suggesting that the absence of
IL-1R1 in neurons has no major impact on cerebral perfusion.
3.5. Deletion of IL-1R1 from cholinergic neurons results in smaller infarct
size, smaller brain oedema and improved functional outcome
Our findings in IL-1R1fl/fl Δ Nestin mice suggest the existence of
parallel, endothelium-independent neuron specific actions of IL-1R1 in
ischaemic brain injury. Therefore, we investigated the effect of IL-1R1
deletion directly in choline-acetyltransferase (ChAT) positive choli-
nergic cells. Forebrain cholinergic neurons play a fundamental role in
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controlling the CNS, establish widespread innervation in the forebrain
and are implicated in cognitive decline and several neurodegenerative
diseases. In addition, brainstem cholinergic neurons control various
physiological functions and regulate general immune response via the
vagus nerve (Hoover, 2017; Mufson et al., 2008; Duris et al., 2017).
There was a significant reduction in infarct size (by 22.4%,
p=0.0279) and brain oedema (by 57.2%, p=0.0255) in IL-1R1fl/fl Δ
ChAT mice when compared to IL-1R1fl/fl mice (Fig. 6A and B). Deletion
of IL-1R1 in cholinergic cells also improved functional outcome as as-
sessed by Garcia’s composite neurological score (Fig. 6D, p= 0.0263),
whilst a non-significant trend for improved sensory-motor function was
observed by using the Bederson score (Fig. 6C).
3.6. Removal of IL-1R1 signalling ubiquitously or from platelets and
myeloid cells does not influence brain injury after cerebral ischaemia
We chose to flox exon 5 in the il-1r1 locus to effectively eliminate all
IL-1R1 isoforms in order to generate a new line of IL-1R1fl/flmice where
the receptor is fully eliminated (Fig. 7A). Ubiquitous deletion of IL-1R1
was confirmed with PCR from tail samples and a lack of IL-1R1 im-
munoreactivity in the brain (Fig. 7B). In spite of the complete absence
of functional IL-1R1 in these mice and the marked protective effect of
endothelial and neuronal IL-1R1 deletion, ubiquitous IL-1R1 KO mice
subjected to cerebral ischaemia showed no difference in infarct size
(Fig. 7C), oedema (Fig. 7D) and neurological outcome (Fig. 7E) com-
pared to control WT (IL-1R1fl/fl) mice. To investigate whether IL-1R1
signalling in blood-borne cells could explain the lack of protection in
ubiquitous IL-1R1 KO mice, but significantly reduced brain injury after
brain endothelial and neuronal IL-1R1 deletion, we deleted IL-1R1 from
platelets and myeloid cells. Constitutive deletion of IL-1R1 in platelets
or myeloid cells by crossing IL-1R1fl/fl mice with PF4-Cre mice and
LysM-Cre mice, respectively, had no significant impact on brain injury
and other parameters measured (Fig. 7F–H). Thus, endothelial and IL-
1R1 in cholinergic neurons contributes to brain injury independently of
IL-1 actions on platelets and myeloid cells.
4. Discussion
In this study we have identified the cerebrovascular endothelium
and cholinergic neurons as major targets for IL-1 action after ischaemic
stroke. Specific deletion of the IL-1R1 in brain endothelial cells reduced
infarct volume and other outcome measures (i.e. BBB disruption, neu-
rological deficit) induced by transient MCAo to a level comparable to
that seen with IL-1Ra treatment in a number of previous studies
(Maysami et al., 2016; McCann et al., 2016). We show for the first time
that brain endothelial IL-1 actions have a robust and very early impact
on cortical perfusion after brain injury, which is associated with facil-
itation of vascular activation and leukocyte infiltration. In contrast,
Fig. 2. Brain endothelial IL-1R1 deletion reduces vascular activation. Immunostaining with ICAM-1 (co-stained with lectin to identify cerebral blood vessels) showed
increased ICAM-1 cerebrovascular staining in the ipsilateral hemisphere when compared to the contralateral side 24 h after MCAo (A), and deletion of IL-1R1 on the
brain endothelium decreased ICAM-1 expression (IL-1R1fl/fl Δ Slco1c1 mice treated with tamoxifen) in comparison to control (IL-1R1fl/fl Δ Slco1c1 mice treated with
vehicle) (B). VCAM-1 Immunostaining (co-stained with lectin to identify cerebral blood vessels and VWF for endothelial cell activation) showed increased VCAM-1
cerebrovascular staining in the ipsilateral hemisphere when compared to the contralateral side after stroke (C), and deletion of IL-1R1 on the brain endothelium
decreased VCAM-1 expression (IL-1R1fl/fl Δ Slco1c1 mice treated with tamoxifen) in comparison to control (IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle) (D). No change
in the number of VWF-positive blood vessels was seen (E). IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle; n= 10, IL-1R1fl/fl Δ Slco1c1 mice treated with tamoxifen;
n= 11, IL-1R1fl/fl treated with tamoxifen; n=7. *p≤ 0.05, **p≤ 0.01. Region of interest MFI measured in arbitrary units (AU). Data are expressed as
means ± SEM.
R. Wong et al. Brain, Behavior, and Immunity 76 (2019) 126–138
131
neuronal IL-1R1 deletion reduced infarct size whilst having no influ-
ence on cerebral perfusion changes after stroke. This confirms IL-1
actions on the cerebrovascular endothelium and neurons as key events
in mechanisms of IL-1-driven inflammation that depend on different
mechanisms and potentially different time windows in response to
stroke.
Brain endothelial cells are activated by IL-1 after stroke via binding
of IL-1R1, leading to the upregulation of ICAM-1, VCAM-1 and P-
Selectin expression, as well as various chemokines, resulting in neu-
trophil adhesion and infiltration (Thornton et al., 2010). We have de-
monstrated previously in vitro that IL-1 leads to the infiltration of
neutrophils that acquire a neurotoxic phenotype (Allen et al., 2012).
We now show in vivo that mice lacking IL-1R1 on brain endothelial cells
exhibit reduced cerebrovascular expression of ICAM-1 and VCAM-1
that is accompanied by a marked reduction in the number of neu-
trophils infiltrating the brain in response to stroke, supporting our
previous in vitro findings. Neutrophils are amongst the first cells to in-
filtrate the brain during cerebral ischaemia, amplifying cerebral in-
flammatory responses that exacerbate further BBB disruption, cerebral
oedema and brain injury, leading to larger infarcts (Jin et al., 2010;
Segel et al., 2011). Due to the key roles of neutrophils in ischaemic
brain injury, it is not surprising they are of great interest as therapeutic
targets (Jickling et al., 2015), and IL-1 acting on the brain endothelium
to attract neutrophils and their neurotoxic intracellular content could
potentially be a key mechanism. It is currently unclear whether neu-
trophil-dependent mechanisms contribute to changes in cerebral per-
fusion and/or BBB breakdown within the first hours after cerebral
ischaemia. We have shown previously that IL-1-mediated systemic
inflammatory mechanisms involve neutrophils, platelets and also sti-
mulate endothelin-1 expression (Thornton et al., 2010; Denes et al.,
2007; Murray et al., 2014), which could alter cerebral perfusion. Thus,
IL-1 actions on the cerebrovascular endothelium could interact with
several other IL-1 dependent (and independent) inflammatory processes
in the mechanisms of brain injury. The surprising finding that the ab-
sence of functional IL-1R1 signalling in brain endothelial cells pro-
foundly determines cerebral perfusion within the first hours – a ther-
apeutically critical time window after stroke - suggests that timely
blockade of IL-1 actions could have diverse beneficial effects on blood
flow recovery and the associated inflammatory response that collec-
tively determine functional outcome. Importantly, these effects of IL-1
on brain endothelial cells are potentially modifiable without the need
for direct CNS actions of a drug, opening up the possibility of targeted
anti-IL-1 therapies (e.g. neutralising antibodies) that would not typi-
cally show brain penetration.
We also observed microglial cell activation in the peri-infarct area
but this activation was not affected by deletion of IL-1R1 in the brain
endothelial cells or in the absence of neuronal IL-1 signalling. As well as
changes to activation state due to cerebral injury, microglia also pro-
liferate when activated (Weinstein et al., 2010). We saw no difference
in the numbers of microglia between any of the treatment groups in the
peri-infarct zone, which could be due to the short (24 h) survival times
used in this study (Denes et al., 2007).
In contrast, deletion of IL-1R1 in IL-1R1fl/fl Δ Nestin mice altered
microglial process coverage of neurons, which indicates changes in
microglia-neuron interactions after stroke. We have demonstrated re-
cently that microglia are key contributors to neuronal network activity
Fig. 3. Brain endothelial IL-1R1 deletion reduces neutrophil cerebrovascular migration but does not influence microglial activation. Immunostaining for neutrophils
using SCJ4 antibody (co-stained with lectin to identify cerebral blood vessels) reveals increased number of neutrophils in the ipsilateral hemisphere 24 h after MCAo
in comparison to the contralateral side (A), and deletion of IL-1R1 on the brain endothelium reduced the number of neutrophils (IL-1R1fl/fl Δ Slco1c1 mice treated with
tamoxifen) in comparison to control (IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle) (B). Immunostaining for microglia using Iba1 (co-stained with lectin to identify
cerebral blood vessels) revealed no differences in cell number (C), but did show increased cell activation in the damaged region after stroke. However, no differences
in activation states were found between experimental groups (D). IL-1R1fl/fl Δ Slco1c1 mice treated with vehicle; n= 10, IL-1R1fl/fl Δ Slco1c1 mice treated with
tamoxifen; n= 11, IL-1R1fl/fl treated with tamoxifen; n=7. *p≤ 0.05. Data are expressed as means ± SEM.
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changes in the injured brain in vivo and an absence of microglia leads to
markedly augmented neuronal injury after stroke (Szalay et al., 2016).
This is likely due in part to an early protective action of microglia
against excitotoxicity in the evolving penumbra (Szalay et al., 2016),
which is associated with increased microglial process coverage of
neurons that increases with higher level of neuronal activity. These
results are consistent with observations of microglial actions on ex-
citotoxicity using repetitive supramaximal stimulation and the effect of
IL-1 on microglial process convergence toward neuronal axons in brain
slices (Kato et al., 2016; Eyo et al., 2016). Increased microglial process
coverage after neuronal, but not endothelial deletion of IL-1R1, could
be linked to improved microglial control of neuronal activity, which
should be investigated in detail in further studies.
To investigate the neurochemical phenotype of neurons that may
mediate detrimental IL-1 effects via IL-1R1 signalling in the area of the
brain supplied by the MCA, we chose to selectively eliminate IL-1R1
from cholinergic neurons. Cholinergic cells in the basal forebrain and
the brainstem give rise to widespread innervation of the striatum
Fig. 4. IL-1R1fl/fl Δ Nestin mice are protected against brain injury and alter microglia-neuron interactions. Immunostaining reveals neuronal expression of cre re-
combinase in IL-1R1fl/fl Δ Nestin mice 48 h after tamoxifen administration (A). IL-1R1 deletion in neurons (IL-1R1fl/fl Δ Nestin mice treated with tamoxifen) reduced
infarct volume (B), but did not significantly alter brain oedema (C) or neurological outcome (D). Dashed line outlines the area of the infarct. Immunofluorescent
assessment of ICAM-1 expression in brain microvessels and CD45-positive leukocytes (arrowheads) (E) reveals no changes in the recruitment of blood-borne cells (F)
and vascular activation (G) in response to neuronal IL-1R1 deletion. The majority of CD45-positive leukocytes were neutrophils containing myloperoxidase (MPO,
arrowheads) (Eii). No differences were seen in the number of activated (Iba1+CD45low) microglia in the striatum, or in the cortex (shown in pictures) (H). In
contrast, microglial process coverage of neurons (arrowheads) was increased in the absence of neuronal IL-1R1 (I). Microglia (Iba1, green) contact neurons (NeuN,
blue) and Annexin V-positive cell debris (red) in the boundary zone of the infarct. Note the markedly reduced number of neurons beyond the Annexin V-positive zone
(dashed line) (J). n= 10. *p≤ 0.05, **p≤ 0.01. All parametric data are expressed as means ± SEM, medians are shown in the case of neurological scores. Scale
bars: A, I, 10 μm; E, J, 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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(Dautan et al., 2014; Zaborszky et al., 2015) and the cerebral cortex.
Besides the strong associations of the cholinergic system with attention,
memory and cognitive function (Eckenstein et al., 1988; Rye et al.,
1984; Yu and Dayan, 2005; Hasselmo and Bower, 1993; Rasmusson and
Dykes, 1988; Jones, 1993), dysfunction of cholinergic neurons is linked
with a wide array of neurodegenerative disorders (Tata et al., 2014).
Atrophy of the basal forebrain cholinergic system is associated with
cognitive impairment (Kilimann et al., 2017) and precedes Alzheimer’s
disease pathology (Schmitz and Nathan Spreng, 2016). The mechan-
isms through which IL-1R1 signalling in cholinergic cells could mediate
brain injury after experimental stoke are presently unclear. However,
interactions between cholinergic pathways and the immune system are
well-documented (Maurer and Williams, 2017). For example, α7 nico-
tinic acetylcholine receptors in astrocytes (Patel et al., 2017) and mi-
croglia (Suzuki et al., 2006) mediate anti-inflammatory effects in-
cluding reduced release of TNFα and protect dopaminergic neurons
against degeneration. In addition, systemic inflammatory responses are
under the control of the cholinergic anti-inflammatory pathway (Rosas-
Ballina and Tracey, 2009) supplied by connections of the vagal nerve.
Activation of vagal neurons leads to smaller brain injury after experi-
mental stroke (Jiang et al., 2014; Ay et al., 2009; Sun et al., 2012),
whilst disruption to this pathway is linked with exacerbated brain
Fig. 5. Endothelial IL-1R1 deletion reduces early perfusion deficits after cerebral ischaemia and reperfusion. Cortical perfusion was assessed by laser speckle contrast
imaging (LSCI) in three adjacent zones (MCA1-MCA3) centred around the primary MCA area towards the midline and rostro-caudal cortical areas (A). IL-1R1fl/fl Δ
Slco1c1 mice show better blood flow recovery at 30min after the induction of reperfusion compared to IL-1R1fl/fl mice, which is most apparent in zones MCA2 and 3
(arrowheads) during the 10min measurement period. Note that cortical blood flow remains relatively uniform between the 2min and 10min representative time
points. Quantitative analysis reveals significantly higher cerebral perfusion in the ipsilateral hemisphere (p≤ 0.01, two-way ANOVA, all ROIs included) with Tukey’s
post hoc multiple comparisons showing differences in the MCA2 and MCA3 zones (p≤ 0.05, n=5). LSCI maps after cerebral ischaemia and reperfusion show no
difference between IL and 1R1fl/fl Δ Nestin mice compared to IL-1R1fl/fl mice (D) and quantitative analysis shows no significant changes in cortical blood flow (E).
*p≤ 0.05, All data are expressed as means ± SEM.
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injury in both ischaemic (Han et al., 2014a,b) and haemorrhagic (Krafft
et al., 2012) stroke. Although IL-1 is known to regulate acet-
ylcholinesterase production and activity of cholinergic neurons (Li
et al., 2000), our data implicate for the first time that functional IL-1R1
in cholinergic neurons directly contribute to brain injury and brain
oedema in an experimental model of brain injury. The important role of
cholinergic innervation in shaping neuronal network activity
throughout the brain, the sensitivity of cholinergic neurons to in-
flammation-mediated injury, or the role of ACh as a modulator of in-
flammation could explain the profound effect of cholinergic IL-1R1
deletion on stroke outcome. In fact, cholinergic neurons have been
shown to be vulnerable to excitotoxicity and inflammation, which may
also be indicated by changes in ACh levels or cholinergic receptors
described in several neurodegenerative disorders (Weiss et al., 1994;
McKinney and Jacksonville, 2005). Thus, IL-1-mediated actions could
promote the dysfunction of cholinergic neurons via different forms of
injury including increased excitoxicity and/or lead to impaired reg-
ulation of central and peripheral inflammatory processes by shaping the
activity of the forebrain cholinergic system (Rosas-Ballina and Tracey,
2009; Allan and Rothwell, 2001), which will need to be investigated in
further studies.
It is widely recognised that peripheral inflammatory disorders pre-
dispose to, or exacerbate, cardiovascular (Grundy et al., 1999) and
cerebrovascular diseases (Catto and Grant, 1995). Experimental ex-
acerbation of ischaemic brain injury by systemic infection and CNS
pathology, induced by atherosclerosis, are mediated by peripheral IL-1
(Thornton et al., 2010; Denes et al., 2007, 2012). The cell targets and
mechanisms of these effects are unknown, but the brain endothelium is
a key candidate, since IL-1 penetrates the brain at very low levels
(Banks et al., 1995). Circulating concentrations of IL-1 never reach high
levels apart from in severe infection (Dinarello, 1996) but circulating
immune cells may deliver IL-1 to the cerebrovasculature (Thornton
et al., 2010), where IL-1R1 expression in the brain is highest (Konsman
et al., 2004). We show, however, that although both platelets and
myeloid cells produce IL-1 and contribute to brain injury after cerebral
ischaemia (Iadecola and Anrather, 2011; Nieswandt et al., 2011), IL-1
actions via IL-1R1 in these cells are not required for these effects.
Previous research found that mice lacking IL-1R1 had comparable
Fig. 6. Deletion of IL-1R1 in cholinergic cells reduces brain injury, brain oedema and improves functional outcome after stroke. Deletion of IL-1R1 from cholinergic
neurons (IL-1R1fl/fl Δ ChAT mice) results in reduced infarct size (A) and brain oedema (B). A non-significant trend for improved sensory-motor function is seen in IL-
1R1fl/fl Δ ChAT mice (C), whilst functional outcome is significantly improved in these animals based on Garcia’s composite neurological score. n= 10 (IL-1R1fl/fl) and
n= 9 (IL-1R1fl/fl Δ ChAT) (D). *p≤ 0.05, All parametric data are expressed as means ± SEM, medians are shown in the case of neurological scores.
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infarct volumes to wild-type (WT) animals (Touzani et al., 2002). Since
in these IL-1R1 KO mice the expression of a truncated form of IL-1R1
could not be excluded (Qian et al., 2012), when generating our IL-1R1fl/
fl mice, we chose to flox exon 5 in the il-1r1 locus to effectively elim-
inate all IL-1R1 isoforms (Abdulaal et al., 2016). This new ubiquitous
deletion of IL-1R1 did not significantly influence brain injury after
stroke in the present experimental model, similar to what was found
previously in other IL-1R1 KO mouse strains (Diem et al., 2003). It is
possible therefore that a complete absence of IL-1R1 signalling could
involve presently unknown compensatory effects and/or that beneficial
actions via IL-1R1 might exist in the periphery or on other cells in the
brain. We have not been able to explore such compensatory or poten-
tially beneficial effects of IL-1 signalling in the present study, which we
recognise as a limitation, and something that is the focus of ongoing
future work. The protective effects of systemic IL-1Ra in different
models of brain injury are widely recognised (Maysami et al., 2016),
therefore further understanding of the cell-specific actions of IL-1 will
need to be better understood to achieve a maximal potential for the
therapeutic blockade of IL-1 actions in brain diseases.
In conclusion, brain endothelial and neuronal (cholinergic) IL-1R1
are key contributors to the detrimental actions of IL-1 in the brain after
stroke (Fig. 8). Cell-specific targeting of IL-1R1 in the brain could have
major therapeutic benefit in stroke and other cerebrovascular disease
by allowing more selective targeting, improving efficacy and reducing
any potential side effects.
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mice expressing K14 Cre (A). IL-1R1−/− mice show
deletion of IL-1R1 protein expression in blood vessels
labelled with tomato lectin (B). Infarct size (C), brain
oedema (D) and neurological outcome (E) are not
different in IL-1R1−/− mice compared to IL-1R1fl/fl
mice. Deletion of IL-1R1 from platelets (IL-1R1fl/fl Δ
PF4 mice) or from myeloid cells (IL-1R1fl/fl Δ LysM
mice) does not influence infarct size (F), brain oe-
dema (G), and neurological scores (H) after experi-
mental stroke. n= 13 (IL-1R1fl/fl), 10 (IL-1R1−/−) in
B–D; n= 14 (IL-1R1fl/fl), 13 (IL-1R1fl/fl Δ PF4) and 12
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